Efficacy of omalizumab in the treatment of atopic dermatitis: A pilot study
The DOI matches its Crossref record.
Abstract
Omalizumab is a unique biologic therapeutic drug approved for treating atopic patients with moderate to severe persistent allergic asthma with a serum IgE ranging from 30 to 700 IU/mL. This study was performed to examine the efficacy of omalizumab for the treatment of atopic dermatitis (AD), a disease with significant morbidity. A prospective analysis was performed to assess the efficacy of omalizumab in 21 patients with moderate to severe persistent allergic asthma and AD. Patients were stratified into the following groups: very high IgE (>700 IU/mL), high IgE (186-700 IU/mL), and normal IgE (0-185 IU/mL). AD severity was assessed at 0, 1, 3, 6, and 9 months via an Investigator Global Assessment index. Twenty-one patients (14-64 years old) were evaluated. Pretreatment IgE levels ranged from 18.2 to 8396 IU/mL, (mean IgE level was 1521 IU/mL). All 21 patients showed clinical and statistically significant improvement of their atopic dermatitis (p<0.00052). In conclusion, this study indicates that omalizumab is effective in treating AD in patients with moderate to severe persistent allergic asthma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
IgE and mast cells in allergic disease
Galli, S. J., & Tsai, M. (2012) · Nature Medicine · doi:10.1038/nm.2755 · Cited by 1,799
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14891 · Cited by 1,181
Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14888 · Cited by 684
Guidelines for treatment of atopic eczema (atopic dermatitis) Part I
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04635.x · Cited by 683
Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
Werfel, T., Allam, J.-P., Biedermann, T., Eyerich, K., Gilles, S., Guttman-Yassky, E., Hoetzenecker, W., Knol, E., Simon, H.-U., Wollenberg, A., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.010 · Cited by 594
IgE, Mast Cells, and Eosinophils in Atopic Dermatitis
Liu, F.-T., Goodarzi, H., & Chen, H.-Y. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-011-8252-4 · Cited by 470
Atopic dermatitis: A practice parameter update 2012
Schneider, L., Tilles, S., Lio, P., Boguniewicz, M., Beck, L., LeBovidge, J., Novak, N., Bernstein, D., Blessing-Moore, J., Khan, D., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.12.672 · Cited by 417
Guidelines for treatment of atopic eczema (atopic dermatitis) Part II
Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink‐Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A. P., et al. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04636.x · Cited by 360
Immunology of atopic eczema: overcoming the Th1/Th2 paradigm
Eyerich, K., & Novak, N. (2013) · Allergy · doi:10.1111/all.12184 · Cited by 325
ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis
Darsow, U., Wollenberg, A., Simon, D., Taïeb, A., Werfel, T., Oranje, A., Gelmetti, C., Svensson, A., Deleuran, M., Calza, A., et al. (2010) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2009.03415.x · Cited by 307
Beneficial Effects of Marine Algal Compounds in Cosmeceuticals
Thomas, N., & Kim, S.-K. (2013) · Marine Drugs · doi:10.3390/md11010146 · Cited by 302
Potential pharmacological applications of polyphenolic derivatives from marine brown algae
Thomas, N. V., & Kim, S.-K. (2011) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2011.09.004 · Cited by 269
Heil, P. M., Maurer, D., Klein, B., Hultsch, T., & Stingl, G. (2010) · JDDG: Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07497.x · Cited by 197
Armstrong, A. W., Johnson, M. A., Lin, S., Maverakis, E., Fazel, N., & Liu, F.-T. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2014.2299 · Cited by 90
Omalizumab for atopic dermatitis: case series and a systematic review of the literature
Holm, J. G., Agner, T., Sand, C., & Thomsen, S. F. (2017) · International Journal of Dermatology · doi:10.1111/ijd.13353 · Cited by 71
Targeting IgE in Severe Atopic Dermatitis with a Combination of Immunoadsorption and Omalizumab
Zink, A., Gensbaur, A., Zirbs, M., Seifert, F., Suarez, I., Mourantchanian, V, Weidinger, S., Mempel, M., Ring, J., & Ollert, M. (2016) · Acta Dermato Venereologica · doi:10.2340/00015555-2165 · Cited by 67
“…in AD (19), studies with omalizumab typically had very ambivalent re-sults: some showed a benefit for patients with AD (4, 5), some rejected this treatment approach (6, 7) and others discussed the high IgE level in AD as a possible limitation for a promising use of this anti-IgE antibody (8–10).”
Metadata
- Authors
- Sheinkopf, L. E., Rafi, A. W., Do, L. T., Katz, R. M., & Klaustermeyer, W. B.
- Venue
- Allergy and Asthma Proceedings
- Publisher
- Oceanside Publications Inc.
- Published
- 2008-09-01
- Volume
- 29
- Issue
- 5
- Pages
- 530-537
- ISSN
- 1088-5412 (ISSN-L)
- OpenAlex
- W1992103497
- Cited by
- 150
- References
- 0
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.